Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
Melanoma research continues to lead the way in new immunotherapies
For recipient of the ESMO Lifetime Achievement Award, Prof. John Haanen, melanoma research has provided him with a career full of innovation, but there is always more to explore
Eftilagimod alpha plus pembrolizumab shows promise in HNSCC with negative PD-1 expression
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
Doublet immunotherapy consolidates its role in hepatocellular carcinoma
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Harnessing the power of the gut microbiome in colorectal cancer
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
No significant survival benefits reported for perioperative chemoimmunotherapy in resectable G/GEJ cancers
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting
Cancer Research
The promise of immuno-oncology in the neoadjuvant setting
Recent data from studies show novel pre-operative therapeutic options, but many pending issues need to be addressed
PD-1 inhibition plus chemoradiotherapy is effective across ethnicities in locally advanced cervical cancer
However, studies highlight cost as an obstacle to widespread accessibility in some countries
Durvalumab plus olaparib show sustained PFS improvements in newly diagnosed non-BRCA-mutated ovarian cancer
While updated results from the DUO-O trial appear promising, they are not conclusive due to the study design